Neuroleptic malignant syndrome: A review and report of six cases

Journal of the Medical Association of Thailand

Volumn 89, Issue 12, 2006, Pages 2155-2160

  Kasantikul, Duangjai ^a   Kanchanatawan, Buranee ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Catatonia; Neuroleptic malignant syndrome; Serotonin syndrome

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETHANECHOL; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; CREATINE KINASE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIANEPTINE; TRAZODONE; TRIHEXYPHENIDYL; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ADOLESCENT; ADULT; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DELIRIUM TREMENS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL DEFICIENCY; MORTALITY; MULTIINFARCT DEMENTIA; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHIATRIC DEPARTMENT; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE ATTEMPT; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 33845633977     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Gupta S, Nihalani ND. Neuroleptic malignant syndrome: a primary care perspective. Prim Care Companion. J Clin Psychiatry 2004; 6: 191-4.
2. Ananth J, Aduri K, Parameswaran S, Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica 2004; 16: 219-28.
3. nd ed. Washington, DC: American Psychiatric Publishing; 2003.
4. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42: 277-85.
5. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464-70.
6. Tanii H, Fujita K, Okazaki Y. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal. Am J Psychiatry 2006; 163: 547-8.
7. Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005; 162: 812.
8. Askin R, Herken H, Derman H. Recurrent neuroleptic malignant syndrome: a case report. Int Med J 2000; 7(Pt 4): 287-8.
9. Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002; 22: 252-6.
10. Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 187-94.
11. Hall RC, Appleby B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005; 98: 114-7.
12. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG, Christodoulou GN. Olanzapine-associated neuroleptic malignant syndrome: is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry 2003; 2: 10.
13. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry 1996; 29: 159-61.
14. Thomas P, Maron M, Rascle C, Cottencin O, Vaiva G, Goudemand M. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry 1998; 43: 303-5.
15. Gold R, Lenox RH. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J Clin Psychiatry 1995; 56: 476-83.